Cyane-carvone, a synthetic derivative of carvone, inhibits inflammatory response by reducing cytokine production and oxidative stress and shows antinociceptive effect in mice.
Cyane-carvone (CC) was studied to elucidate its anti-inflammatory, antinociceptive, and antioxidant effects in Mus musculus. Anti-inflammatory (bradykinin, histamine, prostaglandin E2, serotonin, and carrageenan) and antinociceptive (acetic acid and formalin) models were utilized. Myeloperoxidase activity, interleukin (IL)-1β, tumor necrosis factor alpha (TNF-α), and glutathione (GSH) levels were evaluated. Analysis of variance followed by Student-Newman-Keuls' test was done. Results were compared with control groups (significantly when p < 0.05). In bradykinin, histamine, prostaglandin E2, and serotonin tests, 75 mg/kg CC decreased significantly paw edema (t = 30, 60, 90, and/or 120 min). In carrageenan test, 50 and 75 mg/kg CC (t = 3 h and t = 4 h) and 25 mg/kg CC (t = 4 h) decreased significantly paw edema. CC (75 mg/kg) inhibited significantly mieloperoxidase activity and decreased IL-1β and TNF-α, and all doses increased GSH levels. CC (75 mg/kg) decreased significantly the number of contortions of animals and time of licking (phase 2). CC showed anti-inflammatory, antinociceptive, and antioxidant effects in mice.
Laboratório de Pesquisa em Neuroquímica Experimental, Curso de Farmácia, Universidade Federal do Piauí, Campus Universitário Ministro Petrônio Portella, Bairro Ininga, 64049-550, Teresina, Piauí, Brazil.
Thiago Henrique Costa
TH
Marques
Maria Leonildes Boavista Gomes Castelo Branco
ML
Marques
Jand-Venes R
JV
Medeiros
Renan Oliveira
RO
Silva
André Luiz
AL
dos Reis Barbosa
Tamires Cardoso
TC
Lima
Damião Pergentino
DP
de Sousa
Rivelilson Mendes
RM
de Freitas
D000700:Analgesics / Q000494:pharmacology*; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000494:pharmacology*; D000975:Antioxidants / Q000494:pharmacology; D001920:Bradykinin / Q000037:antagonists & inhibitors; D002351:Carrageenan / Q000037:antagonists & inhibitors; D000081005:Cyclohexane Monoterpenes; D016207:Cytokines / Q000096:biosynthesis*; D015232:Dinoprostone / Q000037:antagonists & inhibitors; D004487:Edema / Q000188:drug therapy; D005978:Glutathione / Q000378:metabolism; D006633:Histamine Antagonists / Q000494:pharmacology; D007249:Inflammation / Q000188:drug therapy; D053583:Interleukin-1beta / Q000378:metabolism; D008297:Male; D051379:Mice; D039821:Monoterpenes / Q000737:chemistry / Q000494:pharmacology*; D018384:Oxidative Stress / Q000187:drug effects*; D010146:Pain / Q000188:drug therapy; D009195:Peroxidase / Q000378:metabolism; D012702:Serotonin Antagonists / Q000494:pharmacology; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism
D000700:Analgesics; D000893:Anti-Inflammatory Agents; D000975:Antioxidants; D000081005:Cyclohexane Monoterpenes; D016207:Cytokines; D006633:Histamine Antagonists; D053583:Interleukin-1beta; D039821:Monoterpenes; D012702:Serotonin Antagonists; D014409:Tumor Necrosis Factor-alpha; C006923:carvone; D002351:Carrageenan; D009195:Peroxidase; D005978:Glutathione; D015232:Dinoprostone; D001920:Bradykinin